1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
(
- Contribution to journal › Article
-
Mark
Targeting TUBG1 in RB1-negative tumors
2025) In FASEB journal : official publication of the Federation of American Societies for Experimental Biology 39(5).(
- Contribution to journal › Article
- 2024
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
(
- Contribution to journal › Article
-
Mark
HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis
(
- Contribution to journal › Article
-
Mark
Long-Term Pattern of Psychotropic Medication Uses Among Swedish Parents of Children Diagnosed With Cancer
(
- Contribution to journal › Article
- 2022
-
Mark
Sedation in specialized palliative care : A cross-sectional study
(
- Contribution to journal › Article
-
Mark
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
(
- Contribution to journal › Article
- 2019
-
Mark
ABC transporters as cancer drivers : Potential functions in cancer development
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Targeted immunotherapies overtaking emerging oncology market value based growth
(
- Contribution to journal › Letter
-
Mark
Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies : a pooled analysis of 25 randomized clinical trials
2015) In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 36(5). p.82-3471(
- Contribution to journal › Article